DAIC

NOVEMBER 8, 2024

tim.hodson Fri, 11/08/2024 - 13:23 Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device.

Innovation 52

Innovation Peripheral Arterial Disease Technology Ultrasound 52

DAIC

MARCH 20, 2024

milla1cf Wed, 03/20/2024 - 18:50 March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve below-the-knee resorbable magnesium scaffold (BTK RMS). CLTI is associated with high rates of amputation and mortality as well as high care costs.1

Peripheral Arterial Disease 105

Peripheral Arterial Disease Innovation Technology Coronary Artery Disease 105

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. Presented at EuroPCR 2024. 3 “We very much appreciate FDA’s breakthrough designation recognition of the bioadaptor technology,” continued Sirhan. JACC 2020.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

DAIC

JANUARY 18, 2024

Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheral arterial disease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform.

Angioplasty 105

Angioplasty Peripheral Arterial Disease Kidney Disease Laboratory 105

DAIC

MAY 1, 2024

The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine.

Interventional Cardiology 105

Interventional Cardiology Aortic valve TAVR Peripheral Arterial Disease 105

DAIC

MARCH 27, 2024

The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronary artery disease. Image courtesy: Elixir Medical christine.book Wed, 03/27/2024 - 10:21 March 27, 2024 — Elixir Medical has announced it has been granted Breakthrough Device Designation by the U.S.

Peripheral Arterial Disease 111

Peripheral Arterial Disease Ischemia Technology Coronary Artery Disease 111

DAIC

MAY 31, 2024

Getty Images milla1cf Fri, 05/31/2024 - 09:43 May 31, 2024 — Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.”

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104